biosimilars

How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
Fierce Pharma
JNJ
Remicade
biosimilars
Pfizer
Inflectra
Flag link:
Poor test results for Roche cloud growth prospects
Poor test results for Roche cloud growth prospects
Yahoo/Reuters
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link:
Facing a critical August deadline, House passes bill to reauthorize FDA user fee programs
Facing a critical August deadline, House passes bill to reauthorize FDA user fee programs
Endpoints
FDA
user fees
generics
devices
biosimilars
Flag link:
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
Flag link:
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
In latest setback, another Coherus partner bails out on Amgen biosimilar deal
Endpoints
Coherus
Amgen
biosimilars
Daiichi Sankyo
CHS-0214
rheumatoid arthritis
Enbrel
Flag link:
Novartis scores second biosimilar approval in two weeks
Novartis scores second biosimilar approval in two weeks
BioPharma Dive
Novartis
biosimilars
Enbrel
Europe
Sandoz
Erelzi
Roche
Rituxan
Flag link:
Coherus cuts staff after FDA red light
Coherus cuts staff after FDA red light
BioPharma Dive
Coherus Biosciences
layoffs
FDA
biosimilars
Amgen
Neulasta
Flag link:
FDA Rejects Pfizer's Anemia Drug Biosimilar
FDA Rejects Pfizer's Anemia Drug Biosimilar
Xtalks
FDA
Pfizer
biosimilars
Epogen
Amgen
anemia
Flag link:
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?
Motley Fool
AbbVie
biosimilars
Humira
Clovis Oncology
Rubraca
Novartis
Regeneron
Eylea
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
FDA rejects Pfizer's Epogen biosimilar for the second time
FDA rejects Pfizer's Epogen biosimilar for the second time
Fierce Pharma
FDA
Pfizer
biosimilars
Epogen
Flag link:
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Novartis wins another biosimilar round with an OK for its Rituxan copycat
Endpoints
Novartis
biosimilars
Rituxan
Roche
Sandoz
Flag link:
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Amgen loses its bid to delay biosimilars as SCOTUS hands Novartis a victory
Endpoints
Amgen
Novartis
Supreme Court
biosimilars
Neulasta
FDA
Coherus Biosciences
Flag link:
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
Fierce Pharma
FDA
advisory panels
Pfizer
biosimilars
Amgen
Epogen
Procrit
anemia
JNJ
Flag link:
UK watchdog accuses Merck of restricting biosimilar competition
UK watchdog accuses Merck of restricting biosimilar competition
Drug Delivery Business News
Merck
biosimilars
competition
UK
Remicade
Flag link:
Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review
Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review
Fierce Pharma
Pfizer
Epogen
biosimilars
FDA
advisory panels
Amgen
anemia
Flag link:
Sanofi’s insulin biosimilar wins EMA committee recommendation
Sanofi’s insulin biosimilar wins EMA committee recommendation
Drug Delivery Business News
Sanofi
insulin
biosimilars
EMA
Europe
Lispro
Flag link:
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Fierce Pharma
Humira
patents
AbbVie
biosimilars
Flag link:
Novartis pushes further into pain with Durect deal
Novartis pushes further into pain with Durect deal
BioPharma Dive
Novartis
Durect
Sandoz
biosimilars
generics
Posimir
R&D
Flag link:
Amid sales growth, Roche plans defense from biosimilar threats
Amid sales growth, Roche plans defense from biosimilar threats
BioPharma Dive
Roche
biosimilars
Rituxan
Herceptin
Avastin
Flag link: